296 related articles for article (PubMed ID: 37559996)
1. CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events.
Tian C; Wang X; Zhang S
Am J Cancer Res; 2023; 13(7):3140-3156. PubMed ID: 37559996
[TBL] [Abstract][Full Text] [Related]
2. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
Gao HJ; Shang XB; Yu ZT
Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.
Lyons TG; Ku GY
Chin Clin Oncol; 2017 Oct; 6(5):53. PubMed ID: 29129093
[TBL] [Abstract][Full Text] [Related]
4. Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.
Zhou X; Ren T; Zan H; Hua C; Guo X
Front Immunol; 2022; 13():864202. PubMed ID: 35669786
[TBL] [Abstract][Full Text] [Related]
5. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
6. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy.
Liao XY; Liu CY; He JF; Wang LS; Zhang T
Oncol Lett; 2019 Nov; 18(5):5011-5021. PubMed ID: 31612012
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors: a new era for esophageal cancer.
Zou LQ; Yang X; Li YD; Zhu ZF
Expert Rev Anticancer Ther; 2019 Aug; 19(8):731-738. PubMed ID: 31424306
[No Abstract] [Full Text] [Related]
8. Immune checkpoint inhibitors in lung cancer: current status and future directions.
Fan Y; Mao W
Chin Clin Oncol; 2017 Apr; 6(2):17. PubMed ID: 28482670
[TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis.
Gu YM; Shang QX; Zhuo Y; Zhou JF; Liu BW; Wang WP; Che GW; Chen LQ
Front Oncol; 2021; 11():777686. PubMed ID: 34993139
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy.
He M; Yang T; Wang Y; Wang M; Chen X; Ding D; Zheng Y; Chen H
Adv Healthc Mater; 2021 May; 10(9):e2002104. PubMed ID: 33709564
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
[TBL] [Abstract][Full Text] [Related]
17. Current status of cancer immunotherapy for gynecologic malignancies.
Nishio H; Iwata T; Aoki D
Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Vivaldi C; Catanese S; Massa V; Pecora I; Salani F; Santi S; Lencioni M; Vasile E; Falcone A; Fornaro L
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121290
[TBL] [Abstract][Full Text] [Related]
19. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]